The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
The Chemours CompanyNYSE: CC
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables falls 5.4% from a year ago
Net receivables stood at $907M at the end of Q2 FY2026, down 5.4% from a year earlier and up 19.5% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Net receivables amounted to 12.7% of total assets at the end of Q2 FY2026, down 0.1 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -5.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 679M USD
- Year-over-year change
- -11.8%
- 4-year CAGR
- -1.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 679M | -11.8% |
| FY2024 | 2024-12-31 | 770M | +26.2% |
| FY2023 | 2023-12-31 | 610M | -2.6% |
| FY2022 | 2022-12-31 | 626M | -13.1% |
| FY2021 | 2021-12-31 | 720M | — |
Net Receivables vs competitors
How CC compares with its peers on the latest reported figures
- CC's Jun 2026 net receivables of $907M is the 8th highest of the 19 companies compared; the peer median is $689.51M.
- Its year-over-year change of -5.4% is the 18th highest of 19, against a peer median of +11.2%.
- Net receivables amounts to 12.7% of total assets for CC, versus a peer median of 11.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $6.06B | +10.5% | +2.2% | 6.9% | |
| Jun 2026 | $3.91B | +0.5% | +0.3% | 17.4% | |
| Sep 2026 | $3.72B | +23.0% | -11.7% | 10.7% | |
| Sep 2026 | $2.78B | +10.4% | +7.3% | 6.7% | |
| Jun 2026 | $1.83B | -11.0% | -2.5% | 7.3% | |
| Sep 2026 | $1.7B | -3.7% | -5.8% | 8.8% | |
| Jun 2026 | $1.35B | -3.4% | +4.6% | 17.5% | |
| Jun 2026 | $907M | -5.4% | +2.7% | 12.7% | |
| Sep 2026 | $736.1M | +46.6% | +4.3% | 12.6% | |
| Jun 2026 | $731M | +6.1% | -7.1% | 18.4% | |
| Aug 2026 | $648.01M | +15.0% | -4.3% | 11.9% | |
| Sep 2026 | $487.96M | +11.9% | -4.1% | 16.7% | |
| Jun 2026 | $376.5M | +12.7% | +0.4% | 15.9% | |
| Mar 2026 | $287.8M | +0.4% | -16.1% | 14.9% | |
| Sep 2026 | $280.27M | +1.2% | -15.3% | 15.4% | |
| Jun 2026 | $256M | +27.4% | -15.6% | 5.6% | |
| Jun 2026 | $158.1M | +29.8% | +48.1% | 4.9% | |
| Mar 2026 | $94.1M | +22.3% | +4.5% | 7.5% | |
| Mar 2026 | $17.57M | +120.3% | -24.4% | 9.8% | |
| Peer median (excluding CC) | $689.51M | +11.2% | -3.3% | 11.3% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.45B | 1.1B | 1.2B | 713M | 672M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 720M | 626M | 610M | 770M | 679M |
| Inventory | 1.1B | 1.4B | 1.35B | 1.47B | 1.57B |
| Other Current Assets | 0 | 82M | 705M | 71M | 81M |
| Total Current Assets | 3.35B | 3.21B | 3.84B | 3.03B | 3B |
| Property, Plant & Equipment (Net) | 3.38B | 3.41B | 3.48B | 3.44B | 3.35B |
| Goodwill | 102M | 102M | 102M | 46M | 46M |
| Intangible Assets | 6M | 13M | 3M | 3M | 2M |
| Long-term Investments | 169M | 175M | 158M | 152M | 160M |
| Tax Assets | 171M | 152M | 303M | 291M | 254M |
| Other Non-current Assets | 376M | 573M | 374M | 556M | 570M |
| Total Non-current Assets | 4.21B | 4.43B | 4.42B | 4.49B | 4.38B |
| Total Assets | 7.55B | 7.64B | 8.25B | 7.52B | 7.38B |
| Account Payables | 1.14B | 1.21B | 1.13B | 1.12B | 929M |
| Short-term Debt | 25M | 43M | 51M | 54M | 104M |
| Tax Payables | 64M | 42M | 28M | 44M | 0 |
| Deferred Revenue | 3M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 440M | 325M | 1.13B | 554M | 547M |
| Total Current Liabilities | 1.86B | 1.89B | 2.49B | 1.8B | 1.69B |
| Long-term Debt | 3.72B | 3.59B | 3.94B | 4.02B | 4.26B |
| Deferred Tax Liabilities | 49M | 61M | 44M | 35M | 37M |
| Deferred Revenue (Non-current) | 2M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 656M | 793M | 789M | 824M | 927M |
| Total Non-current Liabilities | 4.61B | 4.64B | 5.03B | 5.11B | 5.45B |
| Total Liabilities | 6.47B | 6.53B | 7.51B | 6.91B | 7.13B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 1.75B | 2.17B | 1.78B | 1.72B | 1.22B |
| Accumulated OCI | (364M) | (343M) | (274M) | (367M) | (244M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 1M | 0 | 2M | 1M | 1M |
| Total Equity | 1.08B | 1.11B | 739M | 605M | 251M |
| Total Debt | 3.99B | 3.88B | 4.3B | 4.36B | 4.59B |
| Net Debt | 2.54B | 2.78B | 3.1B | 3.64B | 3.91B |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.